HUTCHMED Reports the Initiation of Tazemetostat in Bridging Study for the Treatment of Follicular Lymphoma in China
Shots:
- The company has initiated a bridging study to evaluate tazemetostat in patients with r/r FL
- The primary objective of the study is to evaluate the efficacy of tazemetostat for r/r FL who have mutations in EZH2 (cohort 1) while the secondary objectives are to evaluate the efficacy in patients who have EZH2 wild-type (cohort 2) and also assess the safety & PK
- Tazemetostat is a methyltransferase inhibitor of EZH2 that was developed by Epizyme. The therapy has been approved in the US for advanced ES and r/r FL under the US FDA accelerated approval. In Aug 2021, HUTCHMED & Epizyme collaborated to research, develop, manufacture, and commercialize tazemetostat in China, Hong Kong, Macau, and Taiwan
Ref: GlobeNewswire | Image: Hutchmed
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
